Baader Bank Aktiengesellschaft Invests $912,000 in Arrowhead Pharmaceuticals, Inc. $ARWR

Baader Bank Aktiengesellschaft acquired a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the fourth quarter, HoldingsChannel reports. The institutional investor acquired 14,194 shares of the biotechnology company’s stock, valued at approximately $912,000.

A number of other large investors have also recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Arrowhead Pharmaceuticals by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock worth $553,077,000 after buying an additional 510,798 shares during the last quarter. Avoro Capital Advisors LLC grew its position in shares of Arrowhead Pharmaceuticals by 2.8% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock worth $375,941,000 after buying an additional 300,000 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of Arrowhead Pharmaceuticals by 3,142.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock worth $71,797,000 after buying an additional 2,017,489 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Arrowhead Pharmaceuticals by 34.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after buying an additional 447,456 shares during the last quarter. Finally, Baker BROS. Advisors LP grew its position in shares of Arrowhead Pharmaceuticals by 77.9% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,670,762 shares of the biotechnology company’s stock worth $57,625,000 after buying an additional 731,588 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Trading Up 2.3%

NASDAQ ARWR opened at $79.69 on Friday. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 1.41. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $14.30 and a twelve month high of $82.26. The firm has a market capitalization of $11.23 billion, a PE ratio of -37.06 and a beta of 1.28. The stock’s 50 day moving average is $65.71 and its 200 day moving average is $61.75.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The company had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. During the same period in the previous year, the company posted $2.75 earnings per share. The firm’s revenue was down 86.4% on a year-over-year basis. Research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.97 earnings per share for the current fiscal year.

Key Headlines Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Arrowhead Pharmaceuticals and maintained a $100 price target, while also raising some medium- and longer-term earnings forecasts, including FY2026 and Q4 2026 estimates. Arrowhead Pharmaceuticals analyst estimate updates
• Positive Sentiment: Sanford C. Bernstein raised its price target from $35 to $46, signaling improved confidence in Arrowhead’s outlook, even though its rating remains Market Perform. Bernstein raises Arrowhead price target
• Neutral Sentiment: HC Wainwright made only small revisions to several quarterly EPS estimates, with some quarters slightly lower and others slightly higher, suggesting no major change in the overall thesis for Arrowhead’s pipeline-driven earnings path. HC Wainwright estimate revisions
• Neutral Sentiment: Recent coverage also highlighted Arrowhead’s ongoing valuation debate and upcoming clinical readouts, which may be keeping investor interest elevated ahead of key catalysts. Multiple important clinical readouts in 2H26
• Negative Sentiment: HC Wainwright trimmed several near-term earnings forecasts for Arrowhead, including Q3 2026, Q1 2027 and Q2 2027, which reflects expectations for continued losses before eventual improvement. Arrowhead near-term earnings estimate cuts

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the sale, the director directly owned 52,012 shares of the company’s stock, valued at approximately $3,998,682.56. The trade was a 5.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James C. Hamilton sold 10,000 shares of the business’s stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the completion of the sale, the insider directly owned 226,958 shares in the company, valued at $17,021,850. This trade represents a 4.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 36,065 shares of company stock worth $2,554,562 over the last ninety days. 3.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ARWR. Morgan Stanley upgraded Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $78.00 to $100.00 in a research report on Tuesday, April 21st. B. Riley Financial lifted their price objective on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, May 6th. Royal Bank Of Canada lifted their price target on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Finally, Sanford C. Bernstein lifted their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $87.80.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.